The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.Most investors are aware of the vast sales potential for the effective new weight loss treatments known as GLP-1 drugs, and the market for them is still relatively quite young. On Tuesday, the Congressional Budget Office (CBO) put a number on one piece of that market's potential. As that figure was large, weight loss drug producer Eli Lilly (LLY 1.70%) saw a nearly 2% bump in its share price in response. That compa ...